Otonomy, Inc. (NASDAQ:OTIC) traded up 5.8% during trading on Thursday . The stock traded as high as $5.70 and last traded at $5.50. 1,682,162 shares were traded during trading, an increase of 104% from the average session volume of 822,908 shares. The stock had previously closed at $5.20.
Several equities research analysts have recently commented on the company. Piper Jaffray Companies reissued a “hold” rating and set a $8.00 price target on shares of Otonomy in a research note on Friday, November 10th. Zacks Investment Research raised Otonomy from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research note on Tuesday. BidaskClub lowered Otonomy from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. J P Morgan Chase & Co raised Otonomy from a “neutral” rating to an “overweight” rating and set a $28.00 price target on the stock in a research note on Tuesday, August 15th. Finally, Cowen and Company reissued an “outperform” rating and set a $55.00 price target on shares of Otonomy in a research note on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $9.15.
Otonomy (NASDAQ:OTIC) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.15. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. The firm had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.43 million. The firm’s quarterly revenue was down 12.8% compared to the same quarter last year. equities analysts forecast that Otonomy, Inc. will post -2.94 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Otonomy, Inc. (OTIC) Trading 5.8% Higher” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/16/otonomy-inc-otic-trading-5-8-higher.html.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
What are top analysts saying about Otonomy Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Otonomy Inc. and related companies.